Recurrent prostate cancer after radical prostatectomy
Conditions
Interventions
Salvage radiotherapy (monotherapy, 70Gy/35fr to the prostate surgical bed) or Salvage radiotherapy (70Gy/35fr to the prostate surgical bed) combined with hormone therapy (LHRH analogue and bicaluta
Sponsors
Department of Urology, Nara Medical University
Urology, Nara Prefecture General Medical Center Urology, Nara City Hospital Urology, Takai Hospital Urology, Yamato Takada Municipal Hospital Urology, Hoshigaoka Medical Center Urology, Tane General Hospital Urology, Matsuzaka Chuo General Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) History of radical prostatectomy for prostate cancer of clinical stage, T1-T3N0M0 2) Pathological stage, T0, T2, T3 3) Pathological stage, N0 or Nx 4) Continuous elevation of serum PSA level, which is 0.2 ng/mL or more 5) Serum PSA level, 1.0 ng/mL or less 6) No radiographcally-detected recurrent lesions 7) No history of radiotherapy to the pelvic for other malignant diseases 8) Age, 20 to 85 yo 9) ECOG-PS 0 or 2 10) No history of blood transfusion within 28 days before the registration 11) Sufficient organ functions within 28 days before the registration 12) Agreement for enrolment in the study with the signed form
Exclusion criteria
Exclusion criteria: Inappropriate for the enrolment by the judgement of the physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Second biochemical recurrence-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Salvage hormone therapy-free survival 2) Metastatic-free survival 3) Cancer-specific survival 4) Overall survival 5) Adverse event 6) Body composition analysis after treatment 7) Health-related quality of life after treatment | — |
Countries
Japan
Contacts
Public ContactMakito Miyake
Nara Medical University Department of Urology
Outcome results
None listed